Literature DB >> 32199780

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Karan Bami1, Sumeet Gandhi2, Howard Leong-Poi1, Andrew T Yan1, Edwin Ho3, Mohammed Zahrani1, Vinay Garg4, Fei Zuo5, Hwee Teoh6, Adrian Quan7, Lawrence A Leiter8, Richard E Gilbert8, Bernard Zinman9, Kevin E Thorpe5, Peter Jüni5, C David Mazer10, Subodh Verma7, Geraldine Ong1, Kim A Connelly11.   

Abstract

Entities:  

Year:  2020        PMID： 32199780     DOI： 10.1016/j.echo.2020.02.005

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN： 0894-7317            Impact factor:   5.251


× No keyword cloud information.
  5 in total

1.  Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.

Authors:  Nick S R Lan; Bu B Yeap; P Gerry Fegan; Gillian Green; James M Rankin; Girish Dwivedi
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-21       Impact factor: 2.357

Review 2.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

3.  Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.

Authors:  Archana Rai; Kim A Connelly; Subodh Verma; C David Mazer; Hwee Teoh; Ming-Yen Ng; Idan Roifman; Adrian Quan; Marina Pourafkari; Laura Jimenez-Juan; Venkat Ramanan; Yin Ge; Djeven P Deva; Andrew T Yan
Journal:  Acta Diabetol       Date:  2022-01-21       Impact factor: 4.280

4.  Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors:  Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal:  Cochrane Database Syst Rev       Date:  2021-10-25

5.  Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.

Authors:  Bradley Sarak; Subodh Verma; C David Mazer; Hwee Teoh; Adrian Quan; Richard E Gilbert; Shaun G Goodman; Karan Bami; Otávio R Coelho-Filho; Vineeta Ahooja; Djeven P Deva; Vinay Garg; Sumeet Gandhi; Kim A Connelly; Andrew T Yan
Journal:  Cardiovasc Diabetol       Date:  2021-10-04       Impact factor: 9.951
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.